Oncogenic KRAS activation is responsible for the most common genetic subtype of lung cancer. Although many of the major downstream signaling pathways that KRAS engages have been defined, these ...
Researchers identified that RASH3D19 creates a positive feedback loop that drives hyperactivity of RAS signaling and leads to tumor growth and treatment resistance Reducing RASH3D19 also reduced tumor ...
“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...
Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...
Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 Representative KRAS-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results